Arbutus Biopharma Corp. (Nasdaq: ABUS) licensed its proprietary lipid nanoparticle technology to Alexion Pharmaceuticals Inc. (Nasdaq: ALXN) for exclusive use in one of Alexion's rare disease programs. Shares of Arbutus Biopharma gained 55 cents to close at $3.40 while Alexion Pharmaceuticals stock slipped 33 cents to close at $122.09.
Arbutus Biopharma licenses technology
March 17, 2017 at 18:58 PM EDT
